Seminar (chemical biology): Kevan Shokat, UCSF & UC Berkeley
<p>Kevan Shokat<br />Department of Cellular and Molecular Pharmacology<br />University of California, San Francisco<br />Department of Chemistry<br />University of California, Berkeley</p>
<p><strong>A systems approach toward polypharmacological drug discovery in cancer</strong></p>
<p>Kinases are highly regulated enzymes with diverse mechanism controlling their catalytic output.  Inhibitor discovery efforts for kinases have produced ATP-competitive compounds, allosteric regulators, irreversible binders, and highly specific inhibitors.  These distinct classes of small molecules have revealed many novel aspects about kinase-mediated signaling and some have progressed from simple tool compounds into clinically validated therapeutics.  My presentation will explore several small-molecule inhibitors for kinases highlighting elaborate mechanisms by which kinase function is modulated.  A complete surprise of targeted kinase drug discovery has been discovery of ATP-competitive inhibitors that behave as agonists, rather than antagonists, of their direct kinase target.  These studies hint at a connection between ATP binding site occupancy and networks of communication that are independent of kinase catalysis.  Indeed, kinase inhibitors have been found that induce changes in protein localization, protein-protein interactions, and even enhancement of catalytic activity of the target kinase.  The relevance of these findings to the therapeutic efficacy of kinase inhibitors and to the future identification of new classes of drug targets will be discussed.</p>
Frick Chemistry Laboratory, Taylor Auditorium  ·  4:30 p.m.– 6:00 p.m.